ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Consolidation radiotherapy refusal in stage I-II Hodgkin lymphoma: sociodemographic determinants and impact on survival outcomes.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConsolidation radiotherapy following chemotherapy represents the standard of care for stage I-II classical Hodgkin lymphoma, yet treatment adherence varies in clinical practice. No previous study has systematically examined the patient characteristics associated with radiotherapy refusal or its impact on survival outcomes. We aimed to identify determinants of consolidation radiotherapy refusal and evaluate its consequences on cause-specific (CSS) and overall survival (OS).
methodsWe conducted a retrospective cohort study using the SEER database (2024 submission, 17 registries) analyzing patients diagnosed with stage I-II Hodgkin lymphoma between 2000 and 2022 who received chemotherapy with indicated consolidation radiotherapy. Patients were categorized based on radiotherapy receipt versus refusal. Chi-square tests compared patient characteristics between groups. Kaplan-Meier methods assessed survival outcomes, and Cox proportional hazards models identified prognostic factors among radiotherapy recipients.
resultsAmong 9150 patients, 141 (1.5%) refused consolidation radiotherapy despite medical indication. Radiotherapy refusal was significantly associated with non-white ethnicity (35.5% vs. 29.9%, p < 0.01) and residence in large metropolitan areas (> 1 million population; 68.8% vs. 59.0%, p < 0.01), with a trend toward higher refusal among women (56.7% vs. 49.0%, p = 0.08). Radiotherapy refusal was significantly associated with inferior survival outcomes: 10-year OS was 83.3% versus 90.0% (p = 0.0014) and 10-year CSS was 90.4% versus 95.0% (p = 0.029) for refusers versus recipients, respectively. Among radiotherapy recipients, multivariable analysis revealed significant socioeconomic disparities, with living with a partner (HR = 0.630, p < 0.001) and higher household income (HR = 0.750, p < 0.001) as protective factors for CSS.
conclusionNon-white ethnicity and residence in a large metropolitan area are risk factors for consolidation radiotherapy refusal in stage I-II Hodgkin lymphoma, with significant adverse associations with survival outcomes. Substantial socioeconomic disparities exist in outcomes among treated patients. These findings highlight the need for targeted educational interventions and culturally sensitive counseling to ensure equitable access to optimal care in this highly curable disease.
Indexed as
Identifiers
41973237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.